MARKSANS PHARMA LTD stock forum
MARKSANS Delivery Buy MARKSANS Above 330 Stop Loss 305 Targets 355-385
MARKSANS Marksans Pharma Limited's Q1 2025 results:
Marksans Pharma Limited reported strong financial performance in Q1 2025, with revenue increasing by 18% year-over-year to ₹5.67 billion.
The company's gross profit margin improved to 54.2% in Q1 2025, up from 52.3% in the previous year's quarter, driven by improved operational efficiency and product mix.
Net profit for the quarter grew by 22% to ₹850 million, with the net profit margin expanding to 15.0% compared to 14.4% in Q1 2024.
The company's debt-to-equity ratio remained low at 1.4%, indicating a healthy financial position and the ability to take on additional debt if needed to fund future growth initiatives.
MARKSANSMarksans Pharma's June-Quarter 2024 results:
Marksans Pharma reported sales of INR 5,906.18 million in the first quarter ended June 30, 2024, compared to INR 5,000.33 million in the same period a year ago, representing a year-over-year increase of 18.1%.
Total revenue for the quarter was INR 6,055.67 million, up from INR 5,101.29 million in the corresponding quarter of the previous year, an increase of 18.7%.
The company's operating income for the quarter was INR 88.31 million, down 7.63% from INR 95.60 million in the previous quarter.
Net income for the quarter was INR 68.66 million, a decrease of 16.20% compared to INR 81.93 million in the previous quarter.
Diluted normalized earnings per share (EPS) for the quarter was INR 1.52, down 17.77% from INR 1.85 in the previous quarter.
The company's selling, general, and administrative expenses increased by 12.07% quarter-over-quarter, while other operating expenses increased by 21.44%.